Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT01115556
Status:
COMPLETED
Last Update Posted:
2018-05-03
First Post:
2010-04-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
Sponsor:
Vitreous -Retina- Macula Consultants of New York
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-05
Start Date Type:
None
Primary Completion Date:
2012-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-01
Completion Date Type:
ACTUAL
First Submit Date:
2010-04-30
First Submit QC Date:
None
Study First Post Date:
2010-05-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-08-07
Results First Submit QC Date:
None
Results First Post Date:
2017-10-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-05-01
Last Update Post Date:
2018-05-03
Last Update Post Date Type:
ACTUAL